International Certifications

Lukas Biomedical's introduction of immunocellular therapy for cancer has been published in top international medical journals such as The Lancet (2000) and Gastroenterology (2015). The results of the Phase III clinical trials for liver cancer patients (n=150 and n=230) demonstrated that a single treatment course could effectively prolong recurrence-free survival time and increase overall survival rates.

說明

International Clinical Evidence

ALL_fac_24E31_W9r5iPZLd6

Source: Published in the Lancet international medical journal in 2000

🔼In 2000, the results of a Phase III clinical trial conducted in Japan were published in the internationally renowned medical journal, The Lancet. The trial involved 150 post-surgical liver cancer patients, with 76 patients randomly assigned to a treatment group receiving memory T cell therapy and 74 patients allocated to a control group. After a 7-year follow-up, the recurrence-free survival rate in the treatment group was significantly higher than in the control group (P<0.008). The trial demonstrated that a single treatment course could delay the recurrence time by up to 1.2 years. No severe side effects were found in the treatment group, with the main side effects being mild fever or local redness and swelling.

ALL_fac_24E31_pGCxQPabt6

Source: 2015 Gastroenterology, an internationally renowned gastrointestinal medical journal

🔼The results of a Phase III clinical trial conducted by South Korea's GCC were published in the internationally renowned gastroenterology journal, Gastroenterology. The trial included 230 post-surgical liver cancer patients in stages I and II, who were randomly assigned to a treatment group receiving memory T cell therapy and a control group. After a 7-year follow-up, the recurrence-free survival rate in the treatment group was significantly higher than that in the control group (P=0.01). The overall survival rate in the treatment group was also superior to that in the control group (P=0.008). No severe side effects were found in the treatment group, with the main side effects being mild fever or local redness and swelling.

ALL_fac_24E31_l3fNXAhlaF

Source: 2019 Cancer Immunology, Immunotherapy International Medical Journal

🔼After completing the clinical trial, GCC obtained drug approval in South Korea and published the results of the Phase IV clinical trial in 2019. The results showed that, 90 months after a single treatment course, the recurrence-free survival rate, overall survival rate, and specific tumor survival rate in the treatment group remained superior to those in the control group (P=0.01, P=0.006, and P=0.02); the hazard ratio in the treatment group was 0.67, indicating a 33% reduction in the recurrence probability. This confirms that the technology can generate long-term memory in cancer patients and effectively prevent cancer recurrence.